How Cerebrolysin Mimics Your Brain's Own Growth Factors to Treat Dementia, Stroke, and Brain Injury

This is a comprehensive narrative review that synthesizes published preclinical and clinical evidence on five neurotrophic factors and their roles in dementia, stroke, and TBI. The review evaluates the biochemistry, signaling networks, and therapeutic potential of these NTFs, with a focus on how Cerebrolysin modulates their expression and activity.

Dementia, stroke, and TBI are among the leading causes of disability worldwide, and treatment options remain limited. This review maps the neurotrophic factor network underlying these conditions and positions Cerebrolysin as a multi-target neuropeptide therapy — an approach that may be more effective than targeting a single growth factor, given how interconnected these signaling pathways are.

Most drug development targets a single molecule or pathway, but brain diseases involve complex networks of interacting growth factors. Cerebrolysin's multi-target approach — engaging neuroplasticity, neurogenesis, angiogenesis, and inflammation simultaneously — represents a different therapeutic philosophy that may better match the complexity of neurological disorders.

As a narrative review, the paper synthesizes existing evidence rather than generating new data. The clinical evidence for Cerebrolysin varies in quality across the three conditions, and some of the clinical trials reviewed may have limitations in design or sample size. The review focuses on selected NTFs rather than the complete neurotrophic landscape.